• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Healthopioid epidemic

6 More States Just Sued the Oxycontin Maker. How It Could Dramatically Alter the Price of an Opioid Settlement

By
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Bloomberg
Bloomberg
Down Arrow Button Icon
May 16, 2018, 6:00 AM ET

Lawsuits filed against Oxycontin maker Purdue Pharma and other drugmakers by Tennessee and Florida cast more doubt about the viability of settlement talks aimed at addressing the U.S. opioid epidemic.

Tennessee Attorney General Herbert Slatery and Florida’s Pam Bondi on Tuesday accused executives of Purdue and other opioid makers and distributors of fueling a public-health crisis by falsely claiming that the synthetic pain medicine wasn’t addictive. They joined more than 20 other states that have sued companies including Purdue, Johnson & Johnson (JNJ) and McKesson Corp. (MCK) over the products.

It’s a twist for Slatery and Bondi, who have been leading settlement negotiations sponsored by a coalition of attorneys general and who’ve deferred from suing makers and distributors of the drug until now. Four other states — North Carolina, Texas, Nevada and North Dakota — also filed opioid suits Tuesday. They were also part of the talks.

“We are disappointed that after months of good faith negotiations working toward a meaningful resolution to help these states address the opioid crisis, this group of attorneys general have unilaterally decided to pursue a costly and protracted litigation process,” Robert Josephson, a Purdue spokesman, said in an emailed statement.

Separately, hundreds of cities and counties are suing the drugmakers and distributors in cases that have been consolidated before a federal judge in Cleveland. The first trial there is scheduled for March, although settlement talks continue.

Quick Settlement?

Lawyers for Stamford, Conn.-based Purdue approached some state attorneys general last year hoping to come up with a quick and affordable settlement of lawsuits seeking to recoup the costs of dealing with the fallout from opioid addictions.

But six people familiar with the talks said this month they were stalled over the question of who will pay to provide extra funding for law-enforcement and drug treatment budgets, Bloomberg News reported May 3. The companies want to test their defenses to the state’s claims before discussing a multibillion-dollar settlement, the people said.

Slatery’s and Bondi’s decision to sue is an acknowledgment opioid makers and distributors won’t get serious about settling suits until the cases go to trial, said Mike Papantonio, a Florida-based lawyer involved in the litigation.

“You can’t accomplish anything in terms of getting companies to admit they are responsible without filing lawsuits,” Papantonio said. “There won’t be any closure on this without litigation.”

Leigh Ann Jones, Slatery’s spokeswoman, said Tennessee’s top lawyer “will continue to play a leadership role in the multistate effort and settlement discussions.”

Bondi said she wanted an out-of-court deal even though she’d joined the ranks of states suing opioid makers. “We will never stop negotiating,” she said at a press conference Tuesday. The suit is a warning that Florida officials are “fully prepared to go to war” if the companies balk at a settlement, she added.

George Jepsen, Connecticut’s attorney general and another leader of the multistate talks, said Slatery and Bondi should press ahead with settlement talks. “We anticipate they will continue in their leadership rolls going forward,” he said.

Other attorneys general have dropped out of the talks because they wanted to move aggressively to recover the billions of dollars spent on the opioid crisis. More than 100 Americans die daily from opioid overdoses.

The consolidated case by the cities and counties is In Re: National Prescription Opiate Litigation, 17-md-2804, U.S. District Court, Northern District of Ohio (Cleveland).

About the Author
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

HealthDietary Supplements
5 Best Nootropics of 2026: Expert Reviewed Supplements
By Christina SnyderFebruary 13, 2026
1 day ago
Big TechGen Z
Analog-obsessed Gen Zers are buying $40 app blockers to limit their social media use and take a break from the ‘slot machine in your pocket’
By Marco Quiroz-GutierrezFebruary 13, 2026
1 day ago
Leesa Sapira Chill
Healthmattresses
Presidents Day Mattress Sales 2026: Find Deals on the Best Sleep Brands
By Christina SnyderFebruary 13, 2026
1 day ago
dog
CommentaryAnimals
You love your dog too much. Blame the broken American Dream and loss of purpose since the pandemic
By Margret Grebowicz and The ConversationFebruary 13, 2026
1 day ago
Healthsleep
Leesa Mattress Review (2026): Rigorously Tested
By Christina SnyderFebruary 12, 2026
2 days ago
Healthsleep
WinkBeds Mattress Review (2026): Rigorously Tested
By Christina SnyderFebruary 11, 2026
3 days ago

Most Popular

placeholder alt text
AI
Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI
By Jake AngeloFebruary 13, 2026
1 day ago
placeholder alt text
Success
MacKenzie Scott says her college roommate loaned her $1,000 so she wouldn't have to drop out—and is now inspiring her to give away billions
By Sydney LakeFebruary 14, 2026
9 hours ago
placeholder alt text
Economy
Some folks on Wall Street think yesterday’s U.S. jobs number is ‘implausible’ and thus due for a downward correction
By Jim EdwardsFebruary 12, 2026
2 days ago
placeholder alt text
Success
Actress Jennifer Garner just took her $724 million organic food empire public. She started her career making just $150 weekly as a ‘broke’ understudy
By Emma BurleighFebruary 13, 2026
1 day ago
placeholder alt text
North America
‘I gave another girl to Kimbal’: Inside Jeffrey Epstein’s honey-trap plan targeting Elon Musk through his brother
By Eva Roytburg and Jessica MathewsFebruary 13, 2026
1 day ago
placeholder alt text
Commentary
Something big is happening in AI — and most people will be blindsided
By Matt ShumerFebruary 11, 2026
3 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.